Cambridge Investment Research Advisors, Inc. Myriad Genetics Inc Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 08, 2019	SELL	$26.93 - $34.7 $647,477 - $834,292	-24,043 Closed	0 $0
Q4 2018 Feb 05, 2019	BUY	$27.23 - $45.56 $26,059 - $43,600	957 Added 4.15%	24,043 $698,000
Q3 2018 Nov 02, 2018	BUY	$37.57 - $50.34 $867,341 - $1.16 Million	23,086 New	23,086 $0

Others Institutions Holding MYGN

# of Institutions

253

Shares Held

90.5M

Call Options Held

100K

Put Options Held

34K

Black Rock Inc. New York, NY

15.2M
Shares

$208 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

10.3M
Shares

$142 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

6.72M
Shares

$92.3 Million
0.03% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

5.18M
Shares

$71.1 Million
0.07% of portfolio
State Street Corp Boston, MA

4.7M
Shares

$64.6 Million
0.01% of portfolio

View Full List

About MYRIAD GENETICS INC

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $1.11B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

More about MYGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account